- Bank of America analysts raised their Lilly price target to $1,397 from $1,341 in a note to clients on Oct. 19, 2026.
- BofA's Q3 physician survey found oral GLP-1s and the Medicare Bridge are US category expanders, with both deriving about 70% of volumes from patients new to GLP-1s.
- Foundayo is at 27% of U.S. oral GLP-1 new starts, and BofA's survey indicates 40% share by 2028/29.
- Novo Nordisk's Wegovy pill is a more formidable competitor than expected, according to CNBC Investing Club, and Lilly must show continued progress in closing the gap.
- Lilly reports Q3 earnings on Oct. 29.
Quotes
“Our 3Q physician obesity survey adds validation for oral GLP-1s and the Medicare Bridge as US category expanders”
“Foundayo is now at 27% of oral GLP-1 new starts, and our survey indicates 40% share by 2028/29.”